Switch to:
Also traded in: Germany, Italy, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 4.25
CTIC's Cash to Debt is ranked lower than
65% of the 932 Companies
in the Global Biotechnology industry.

( Industry Median: 56.57 vs. CTIC: 4.25 )
Ranked among companies with meaningful Cash to Debt only.
CTIC' s Cash to Debt Range Over the Past 10 Years
Min: 0.01  Med: 1.25 Max: No Debt
Current: 4.25
Equity to Asset 0.48
CTIC's Equity to Asset is ranked lower than
72% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. CTIC: 0.48 )
Ranked among companies with meaningful Equity to Asset only.
CTIC' s Equity to Asset Range Over the Past 10 Years
Min: -2.7  Med: 0.03 Max: 0.95
Current: 0.48
-2.7
0.95
F-Score: 1
Z-Score: -23.79
M-Score: -2.81
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -170.58
CTIC's Operating margin (%) is ranked lower than
59% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -76.21 vs. CTIC: -170.58 )
Ranked among companies with meaningful Operating margin (%) only.
CTIC' s Operating margin (%) Range Over the Past 10 Years
Min: -123250  Med: -12079.04 Max: -119.75
Current: -170.58
-123250
-119.75
Net-margin (%) -175.51
CTIC's Net-margin (%) is ranked lower than
60% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -76.14 vs. CTIC: -175.51 )
Ranked among companies with meaningful Net-margin (%) only.
CTIC' s Net-margin (%) Range Over the Past 10 Years
Min: -169773.75  Med: -13740.68 Max: -123.26
Current: -175.51
-169773.75
-123.26
ROE (%) -480.84
CTIC's ROE (%) is ranked lower than
97% of the 855 Companies
in the Global Biotechnology industry.

( Industry Median: -31.69 vs. CTIC: -480.84 )
Ranked among companies with meaningful ROE (%) only.
CTIC' s ROE (%) Range Over the Past 10 Years
Min: -1010.2  Med: -261.49 Max: -124.54
Current: -480.84
-1010.2
-124.54
ROA (%) -93.61
CTIC's ROA (%) is ranked lower than
87% of the 936 Companies
in the Global Biotechnology industry.

( Industry Median: -26.89 vs. CTIC: -93.61 )
Ranked among companies with meaningful ROA (%) only.
CTIC' s ROA (%) Range Over the Past 10 Years
Min: -261.37  Med: -120.92 Max: -51.06
Current: -93.61
-261.37
-51.06
ROC (Joel Greenblatt) (%) -2183.29
CTIC's ROC (Joel Greenblatt) (%) is ranked lower than
71% of the 898 Companies
in the Global Biotechnology industry.

( Industry Median: -360.35 vs. CTIC: -2183.29 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CTIC' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -2837.37  Med: -1865.51 Max: -527.54
Current: -2183.29
-2837.37
-527.54
EBITDA Growth (3Y)(%) -28.50
CTIC's EBITDA Growth (3Y)(%) is ranked lower than
81% of the 489 Companies
in the Global Biotechnology industry.

( Industry Median: -1.10 vs. CTIC: -28.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CTIC' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -84.4  Med: -29.10 Max: 26.4
Current: -28.5
-84.4
26.4
EPS Growth (3Y)(%) -31.00
CTIC's EPS Growth (3Y)(%) is ranked lower than
80% of the 494 Companies
in the Global Biotechnology industry.

( Industry Median: -5.20 vs. CTIC: -31.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CTIC' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -81.3  Med: -23.90 Max: 24.6
Current: -31
-81.3
24.6
» CTIC's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-06)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q1 2015

CTIC Guru Trades in Q1 2015

Paul Tudor Jones 86,900 sh (New)
Jim Simons Sold Out
» More
Q2 2015

CTIC Guru Trades in Q2 2015

Jim Simons 561,124 sh (New)
Paul Tudor Jones 68,600 sh (-21.06%)
» More
Q3 2015

CTIC Guru Trades in Q3 2015

Paul Tudor Jones Sold Out
Jim Simons Sold Out
» More
Q1 2016

CTIC Guru Trades in Q1 2016

Paul Tudor Jones 188,500 sh (New)
Jim Simons 12,200 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with CTIC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:XKRX:046210, NAS:TTNP, NAS:FBIO, TSE:2370, XTAE:RDHL, TPE:1734 » details
Traded in other countries:CEPR.Germany, CTIC.Italy, 0QUJ.UK,
CTI Biopharma Corp is a biopharmaceutical company. The Company is engaged in acquiring, developing & bringing market less toxic, more effective therapies to treat and cure cancer.

CTI Biopharma Corp was incorporated in Washington in 1991. The Company is a biopharmaceutical company focused on the acquisition, development and commercialization of less toxic and more effective ways to treat cancer. The Company is engaged in commercializing PIXUVRI (pixantrone) in the European Union, or the E.U., for multiply relapsed or refractory aggressive non-Hodgkin lymphoma, or NHL, and conducting a Phase 3 clinical trial program of pacritinib for the treatment of myelofibrosis that will support regulatory submission for approval in the United States, or the U.S., and Europe. PIXUVRI is a novel aza-anthracenedione derivative that is structurally related to anthracyclines and anthracenediones, but does not appear to be associated with the same level of cardiotoxic effects. In May 2012, it expanded its late-stage pipeline of product candidates with the acquisition of pacritinib, an oral inhibitor of both Janus Kinase 2, or JAK2, and FMS-like tyrosine kinase, or FLT3, which demonstrated meaningful clinical benefits and good tolerability in myelofibrosis patients in Phase 2 clinical trials. The Company faces competition from a variety of companies focused on developing oncology drugs. It competes with large pharmaceutical companies and with other specialized biotechnology companies. The research, development, testing, manufacture, labeling, promotion, advertising, distribution and marketing, among other things, of its products are extensively regulated by governmental authorities in the U.S. and other countries.

Ratios

vs
industry
vs
history
P/B 2.11
CTIC's P/B is ranked higher than
71% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 3.51 vs. CTIC: 2.11 )
Ranked among companies with meaningful P/B only.
CTIC' s P/B Range Over the Past 10 Years
Min: 1.83  Med: 20.16 Max: 99
Current: 2.11
1.83
99
P/S 2.23
CTIC's P/S is ranked higher than
86% of the 745 Companies
in the Global Biotechnology industry.

( Industry Median: 11.92 vs. CTIC: 2.23 )
Ranked among companies with meaningful P/S only.
CTIC' s P/S Range Over the Past 10 Years
Min: 0.05  Med: 85.36 Max: 7287.5
Current: 2.23
0.05
7287.5
Current Ratio 2.46
CTIC's Current Ratio is ranked lower than
70% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. CTIC: 2.46 )
Ranked among companies with meaningful Current Ratio only.
CTIC' s Current Ratio Range Over the Past 10 Years
Min: 0.38  Med: 2.66 Max: 24.99
Current: 2.46
0.38
24.99
Quick Ratio 2.40
CTIC's Quick Ratio is ranked lower than
67% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.25 vs. CTIC: 2.40 )
Ranked among companies with meaningful Quick Ratio only.
CTIC' s Quick Ratio Range Over the Past 10 Years
Min: 0.38  Med: 2.59 Max: 24.96
Current: 2.4
0.38
24.96
Days Inventory 585.05
CTIC's Days Inventory is ranked lower than
97% of the 446 Companies
in the Global Biotechnology industry.

( Industry Median: 128.00 vs. CTIC: 585.05 )
Ranked among companies with meaningful Days Inventory only.
CTIC' s Days Inventory Range Over the Past 10 Years
Min: 16.31  Med: 1080.10 Max: 8925.18
Current: 585.05
16.31
8925.18
Days Sales Outstanding 4.88
CTIC's Days Sales Outstanding is ranked higher than
92% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 62.87 vs. CTIC: 4.88 )
Ranked among companies with meaningful Days Sales Outstanding only.
CTIC' s Days Sales Outstanding Range Over the Past 10 Years
Min: 2.47  Med: 21.79 Max: 834.94
Current: 4.88
2.47
834.94
Days Payable 3.00
CTIC's Days Payable is ranked lower than
90% of the 442 Companies
in the Global Biotechnology industry.

( Industry Median: 60.55 vs. CTIC: 3.00 )
Ranked among companies with meaningful Days Payable only.
CTIC' s Days Payable Range Over the Past 10 Years
Min: 1049.43  Med: 2592.11 Max: 49126.02
Current: 3
1049.43
49126.02

Valuation & Return

vs
industry
vs
history
Price/Net Cash 3.00
CTIC's Price/Net Cash is ranked higher than
74% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: 5.31 vs. CTIC: 3.00 )
Ranked among companies with meaningful Price/Net Cash only.
CTIC' s Price/Net Cash Range Over the Past 10 Years
Min: 2.7  Med: 31.82 Max: 2652.79
Current: 3
2.7
2652.79
Price/Net Current Asset Value 2.50
CTIC's Price/Net Current Asset Value is ranked higher than
79% of the 726 Companies
in the Global Biotechnology industry.

( Industry Median: 5.18 vs. CTIC: 2.50 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CTIC' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.69  Med: 21.48 Max: 329
Current: 2.5
0.69
329
Price/Tangible Book 2.14
CTIC's Price/Tangible Book is ranked higher than
76% of the 870 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. CTIC: 2.14 )
Ranked among companies with meaningful Price/Tangible Book only.
CTIC' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.6  Med: 17.93 Max: 81
Current: 2.14
0.6
81
Price/Median PS Value 0.03
CTIC's Price/Median PS Value is ranked higher than
99% of the 679 Companies
in the Global Biotechnology industry.

( Industry Median: 0.97 vs. CTIC: 0.03 )
Ranked among companies with meaningful Price/Median PS Value only.
CTIC' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.01  Med: 0.57 Max: 481.5
Current: 0.03
0.01
481.5
Earnings Yield (Greenblatt) (%) -197.64
CTIC's Earnings Yield (Greenblatt) (%) is ranked lower than
96% of the 1024 Companies
in the Global Biotechnology industry.

( Industry Median: -9.20 vs. CTIC: -197.64 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CTIC' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -283.26  Med: 0.00 Max: 0
Current: -197.64
-283.26
0

More Statistics

Revenue (TTM) (Mil) $49.86
EPS (TTM) $ -0.50
Beta0.60
Short Percentage of Float5.59%
52-Week Range $0.25 - 2.46
Shares Outstanding (Mil)282.93

Analyst Estimate

Dec16 Dec17
Revenue (Mil $) 8 162
EPS ($) -0.78 -0.20
EPS without NRI ($) -0.78 -0.20
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
» More Articles for NAS:CTIC

Headlines

Articles On GuruFocus.com
Monday Morning Pre-Market Insights: Celldex Therapeutics, Celladon Corp, CTI BioPharma Corp, TG Ther Jun 01 2015 
Weekly CEO Sells Highlight: Groupon Inc., Cell Therapeutics Inc., Standard Pacific Corp and Dollar G Mar 24 2014 
These 4 Biotech Stocks Are a Buy Now Feb 08 2012 
Cell Therapeutics Inc. (CTIC) CEO James A Bianco sells 50,000 Shares Feb 25 2011 
Cell Therapeutics Inc. (CTIC) CEO James A Bianco sells 50,000 Shares Jan 28 2011 
Weekly CEO Sells Highlight: CTIC, DDR, UNM, BRCM, TC Jan 09 2011 
Cell Therapeutics Inc. (CTIC) CEO James A Bianco sells 250,000 Shares Jan 03 2011 
Cell Therapeutics Inc. (CTIC) CEO James A Bianco sells 200,000 Shares Dec 17 2010 
Cell Therapeutics Inc. (CTIC) CEO James A Bianco sells 150,000 Shares Dec 10 2010 
Cell Therapeutics Inc. (CTIC) CEO James A Bianco sells 100,000 Shares Nov 05 2010 

More From Other Websites
CTI BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD... May 31 2016
ETF’s with exposure to CTI BioPharma Corp. : May 20, 2016 May 20 2016
CTI BioPharma Corp. :CTIC-US: Earnings Analysis: Q1, 2016 By the Numbers May 19 2016
CTI BIOPHARMA CORP Financials May 19 2016
CTI BioPharma Announces Presentations At The American Society Of Clinical Oncology Annual Meeting May 19 2016
CTI BioPharma posts 1Q profit May 10 2016
CTI BioPharma posts 1Q profit May 10 2016
CTI BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial... May 10 2016
CTI BioPharma Reports First Quarter 2016 Financial Results May 10 2016
BrainStorm Cell Therapeutics Reports First Quarter 2016 Financial Results And Provides Corporate... May 10 2016
CTI BIOPHARMA CORP Files SEC form 8-K, Change in Directors or Principal Officers, Submission of... Apr 29 2016
CTI BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD... Apr 28 2016
Preclinical Data Presented At AACR Indicate Pacritinib's Potential To Eradicate Therapy-Resistant... Apr 20 2016
CTI BIOPHARMA CORP Files SEC form 8-K, Other Events Apr 18 2016
CTI BioPharma Announces Presentations at the American Association of Cancer Research Annual Meeting Apr 13 2016
SHAREHOLDER NOTICE: Rosen Law Firm Reminds CTI BioPharma Corp. Investors of Important April 11, 2016... Apr 08 2016
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in CTI... Apr 08 2016
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of... Apr 08 2016
DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against CTI... Apr 08 2016
UPCOMING DEADLINE: Levi & Korsinsky, LLP Notifies Shareholders of CTI BioPharma Corp. of Class... Apr 07 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)